## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Washington, B.O. 200 to										

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								

0.5

hours per response

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

ı	nd Address of	Reporting Person*							er or Tradi			[ DTIL		elationship o eck all applio Directo	cable)	g Pers	10% Ov	/ner
(Last) (First) (Middle) C/O PRECISION BIOSCIENCES, INC.						3. Date of Earliest Transaction (Month/Day/Year) 08/22/2024								Officer (give title Other (specify below)  Chief Research Officer				
302 E. PETTIGREW STREET, SUITE A-100  (Street)  DURHAM NC 27701				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(St		(Zip)											Person				9
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transa Date (Month/D			2A. Deemed Execution Date,			quired, Disposed of, or Benefic  3. Transaction Code (Instr. 8)  4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)			ed (A) or	5. Amou Securitie Beneficia Owned F Reported	nt of es ally following	Form: Dire		ect of Indirect rect Beneficial				
									v	Amount	(D)		Transact (Instr. 3 a	ion(s)			(111501.4)	
		7	Fable II - D (						uired, Di , option					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	ate, T	4. Transactio Code (Instr				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		Derivative Security	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				c	Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amount or Number of Shares					
Restricted Stock Units	(1)	08/22/2024			A		48,657		(2)		(2)	Common Stock	48,657	\$0	48,65	7	D	

## Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
- 2. Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

/s/ John Alexander Kelly,

Attorney-in-Fact for J.

08/23/2024

Jefferson Smith

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.